Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.

TSXV:MPH - Post by User

Medicure Inc

Bullboard Posts

Comment by ipanemaon Oct 04, 2017 7:43am

178 Views

Post# 26774016

RE:RE:RE:Shareholders Value

I think you've hit the nail on the head when you ask the question "did they find that the risks and leverage were too much for them"?

Mr Friesen was 70 in May and below him who are the heirs apparent? Who is going to grow some newly acquired cardiovascular drugs?

The Winnipeg Free Press this morning quotes Friesen as saying "the sale will eventually leave Medicure with between $70m and $80m in cash on its balance sheet". That $4.50 per share say.

I imagine we're not going to have to wait very long before another big announcement.

Bullboard Posts

Debt-free cannabis company set for next stage of growth